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Abstract
Objective and design This study is aimed at exploring the
role of neurokinin-1 receptor (NK-1R) in the development
of allergic rhinitis (AR) in rats.
Methods Sprague–Dawley rats were sensitized and chal-
lenged with ovalbumin to induce AR. The rats were treated
intranasally with saline, control, or NK-1R-specific small
interfering RNA (siRNA) before and during the challenge
period. The numbers of sneezes and nose rubs and amount
of nasal secretion in individual rats were measured. The
levels of NK-1R expression in the nasal mucosal tissues
after the last challenge were determined. The numbers of
eosinophils in the collected nasal lavage fluid and the levels
of serum interleukin (IL)-5 in individual rats were
determined.
Results The levels of NK-1R expression in the nasal
mucosal tissues of the AR rats that had been treated with
saline or control siRNA were significantly higher than
those in the healthy controls and the rats treated with NK-
1R-specific siRNA, demonstrating NK-1R silencing. Fur-
thermore, knockdown of NK-1R expression significantly
reduced the amounts of sneezing, nose rubbing, and nasal
secretions in AR rats. Knockdown of NK-1R expression
also significantly eliminated eosinophil infiltration in the
nasal tissues and reduced the levels of serum IL-5 in rats.
Conclusions Knockdown of NK-1R expression decreased
allergic inflammation in nasal mucosal tissues and
alleviated the allergic rhinitis symptoms, suggesting that
NK-1R may be a critical mediator of the development of
AR.
Keywords Allergic rhinitis  NK-1R  siRNA 
Rats
Introduction
Allergic rhinitis (AR) is a global health problem, which is
associated with severe consequences and disabilities. AR
can negatively affect life quality and school and work
performance in patients [1, 2]. Currently, the precise
pathogenic process of AR is not fully understood. Accu-
mulating evidence has shown that neuro-immune
abnormalities play important roles in the development of
AR [3]. Substance P (SP) is a neuropeptide present in the
upper respiratory tract around the blood vessels and glands,
and between the muscle fibers and epithelial cells. Indeed,
high levels of SP have been detected in the nasal mucosal
tissues of patients with AR [4]. Previous studies have
shown that SP has a wide variety of biologic functions,
such as increasing vascular permeability, stimulating
mucous secretion, and chemotaxis of eosinophils, which
are associated with symptoms in patients with AR [5, 6].
Furthermore, exogenous SP induces nasal obstruction in a
dose-dependent manner in humans and animals [7]. Intra-
nasal treatment with capsaicin to deplete the presynaptic
SP can ameliorate the AR-related symptoms. Hence,
modulation of SP activity will be a promising strategy for
the intervention of AR.
SP exerts its biological actions by binding to a high-
affinity G-protein-coupled receptor denoted NK-1R, which
is expressed by most inflammatory cells, such as mast cells
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and macrophages [8]. NK-1R is also expressed on epithe-
lial cells, vascular endothelial cells, and glandular cells of
the nasal mucous membranes, in combination with SP
along the sensory nerves [9]. A previous study has shown
that induction of AR up-regulates NK-1R mRNA tran-
scription in the nasal mucosa of rats [10]. However, little is
known about the impact of NK-1R silencing on clinical
symptoms and nasal inflammation.
In the present study, we employed a rat model of AR to
test how knockdown of NK-1R expression by nasal treat-
ment with NK-1R-specific siRNA could affect clinical
symptoms and nasal mucosal inflammation in vivo.
Materials and methods
Animals and AR model
Thirty-two male Sprague–Dawley rats weighing 210–240 g
were purchased from Chinese Academy of Sciences,
Shanghai, China. The animals were housed in a pathogen-
free facility with free access to food and water. The
experimental protocols were approved by the Animal Care
and Research Committee of Fudan University.
The animal model of AR was induced as described
previously [11]. Briefly, the rats were sensitized intraperi-
toneally with 0.2 mg ovalbumin (OVA) and 0.2 mg
calmogastrin in 1 ml saline for 7 days. The rats were
subjected to airway sensitization with 0.25 % OVA in
15 ml of saline by ultra-nebulization using a nebulizer
(Dobio Biology Technology, Shanghai, China) for five
consecutive days. One week later, the rats were challenged
intranasally with 100 ll of 1 % OVA in saline 50 ll per
nostril daily for 7 days. The control group (NS) of rats was
administered saline alone.
The AR groups of rats were randomized and treated
intranasally with 100 ll of NK-1R-siRNA (GenePharma,
Shanghai, China) (the NKR group) or control NC-siRNA
(GenePharma) (the NCS group) (1OD260 in 100 ll) on the
day before challenge and days 3 and 6 post-challenge. The
NK-1R-siRNA sequences were sense 50-CCUACAUC
AACCCAGAUCUUU-30 and antisense 50-AGAUCUGGG
UUGAUGUAGGUU-30, and the NC-siRNA sequences
were sense 50-UUCUCCGAACGUGUCACGUdTdT-30
and antisense 50-ACGUGACACGUUCGGAGAAdTdT-30.
The saline control AR group (NSAR) and normal group
were treated with saline. Blood specimens were obtained
from the tail vein of individual rats. The rats were killed
1.5 h after the last challenge, and their nasal mucosal tis-
sues were sampled. One portion of the nasal mucosal
sample was immediately frozen in liquid nitrogen. The
remaining samples were fixed in 4 % paraformaldehyde for
immunohistochemistry analysis.
Observation
The numbers of sneezes and nose rubs were counted for
15 min immediately after the last nasal challenge. A sneeze
in rats was characterized by an explosive expiration just
after deep inspiration. A nose rub in rats was characterized
by an external peri-nasal scratch by their forelimbs. The
nasal secretions were collected as described previously
[12]. One filter-paper strip was inserted into one nostril for
5 min and weighed as the amount of nasal secretion.
Immunohistochemistry
The paraffined nasal mucosal tissue sections (4 lm) were
deparaffined, rehydrated, and subjected to antigen retrieval.
After being blocked with 3 % peroxide-methanol at room
temperature for 10 min and with 2 % bovine serum albu-
min (BSA), the sections were incubated overnight with
rabbit polyclonal antibodies against NK-1R (1:100
dilutions, Thermo Scientific, Rockford, IL, USA). Subse-
quently, the sections were exposed to biotinylated anti-
rabbit and horseradish peroxidase (HRP) conjugated
avidin, followed by development with 3,3-diaminobenzi-
dine (DAB). The sections were counterstained with
hematoxylin. The control sections were not exposed to the
primary antibodies.
Real time RT-PCR
Total RNA was extracted from the nasal mucosal tissues
using Trizol reagent (Invitrogen, Carlsbad, CA, USA),
following the manufacturer’s protocols, and reverse tran-
scribed into cDNA using a cDNA synthesis kit (Promega,
Madison, WI, USA). The relative levels of NK-1R mRNA
transcripts to control b-actin were determined by quanti-
tative RT-PCR on an ABI 7300 (Applied Biosystems,
Foster City, CA, USA) using a SYBR Green-based real-
time RT-PCR kit and specific primers. The sequences of
primers were sense 50-TCTTCTTCCTCCTGCCCTAC
A-30, antisense 50-CATTTCCAGCCCCTCATAATC-30 for
NK-1R (212 bp); and sense 50-CCTCTATGCCAACACA
GT-30, antisense 50-AGCCACCAATCCACACAG-30 for
b-actin (155 bp). The relative levels of NK-1R mRNA to
b-actin were determined by the 2-DDCt method.
Assessment of eosinophil infiltration
The nasal lavage fluid (NLF) was collected 1 h after the
last challenge [13]. Briefly, individual rats were anesthe-
tized and subjected to tracheotomy. Subsequently, a plastic
hose was inserted through the incision of the trachea to the
nasopharynx and the nasal cavities of individual rats were
washed with pre-warmed saline through the tracheal hose
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using a micro pump (300 ll/min for 10 min). The NFL
samples were collected from the anterior nares and cen-
trifuged at 2,000g for 10 min. The cell pellets were re-
suspended by 0.5 ml of Hanks’ solution, and the cells were
stained with ethanol-eosin. The number of eosinophils
in individual samples was counted using a standard
hemocytometer.
IL-5 and NK1-R quantification
Individual serum samples were prepared from individual
rats by centrifugation at 1,000g for 10 min and stored at
-80 C until use. The concentrations of serum interleukin
(IL)-5 in the different groups of rats were determined by
ELISA using an IL-5 detection kit, according to the man-
ufacturer’s instruction (RapidBio Lab, West Hills, CA,
USA). The detection limitation of IL-5 was 10 pg/ml.
The frozen nasal mucosa samples were homogenized,
and total proteins were extracted using cell lysis solution
(Pierce, Rockford, IL, USA). After quantification of pro-
teins, the concentrations of NK-1R in the nasal mucosa
samples were determined by ELISA using the NK-1R-
specific ELISA kit (GBD, San Diego, CA, USA) and
expressed as lg NK-1R per mg total proteins.
Statistical analyses
All data were expressed as the mean ± SD. The differ-
ences between groups were analyzed by analysis of
variance (ANOVA) followed by post-hoc Bonferroni test
using SPSS v11.5 software. A probability value of less than
0.05 was considered statistically significant.
Results
Knockdown of NK-1R expression by specific siRNA
in the nasal mucosa of AR rats
To study the role of NK-1R in AR rats, we measured the
levels of NK-1R expression in the nasal mucosal samples of
the different groups of rats by quantitative RT-PCR,
immunohistochemistry, and ELISA. As shown in Fig. 1,
while moderate levels of NK-1R mRNA transcripts were
detected in the healthy controls (NS), significantly higher
levels of NK-1R mRNA transcripts were found in the saline
vehicle-injected AR (NCS) and NC-siRNA-injected
(NSAR) rats (NCS 16.68 ± 3, NSAR 14.53 ± 4.94 vs. NS
8.5 ± 1.08, p \ 0.05). Treatment with NK-1R-specfic
siRNA significantly reduced the relative levels of NK-1R
mRNA transcripts by nearly 50 % in the nasal mucosal
samples (NKR 8.35 ± 2 vs. NCS 16.68 ± 3, NSAR
14.53 ± 4.94, p \ 0.05, Fig. 1a). A similar pattern of NK-
1R proteins was observed in the different groups of rats, as
determined by ELISA (NS 0.0298 ± 0.0069, NCS
0.0515 ± 0.0091, NSAR 0.0455 ± 0.0047, NKR 0.0291 ±
0.0108, P = 0.0001, Fig. 1b). Further immunohistochem-
istry analyses revealed that NK-1R was expressed in the
cytoplasm of epithelial cells in the nasal mucosa and some
granules (Fig. 2). While weak anti-NK-1R staining was
detected in the nasal mucosal tissues of the NS rats, a
markedly increased intensity of anti-NK-1R staining was
observed in the nasal mucosal tissues of the NCS and NSAR
rats. However, weak anti-NK-1R staining was detected on
the mucociliary layer of the nasal mucosal tissues from the
NKR rats. These three parallel lines of data clearly
Fig. 1 Measurement of NK-1R expression in the nasal mucosal
tissues of rats. After induction of AR and treatment with control or
NK-1R-specific siRNA, the different groups of rats were killed and
the levels of NK-1R expression in the nasal mucosal tissues 1.5 h
after the last challenge were determined by quantitative RT-PCR
(a) and ELISA (b). Data are expressed as the mean ± SD of
individual groups (n = 8 per group) of rats from three separate
experiments. NS Healthy control rats treated with saline, NCS AR rats
treated with control siRNA, NSAR AR rats treated with saline, NKR
AR rats treated with NK-1R-specific siRNA. *P\0.05 vs. NS group.
#P \0.05 vs. NCS or NSAR group
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demonstrated that induction of AR up-regulated NK-1R
expression in the nasal mucosal tissues of rats and that
intranasal treatment with NK-1R-specific siRNA effectively
inhibited NK-1R expression in the nasal mucosal tissues of
rats.
Knockdown of NK-1R expression alleviates AR
symptoms in rats
Animals with AR usually develop sneezing and nose rub-
bing symptoms and have increased amounts of nasal
secretions [14]. To determine the role of NK-1R in AR, we
observed clinical symptoms in the different groups of rats.
Following saline challenge, the NS group of rats displayed
a few sneezes and nose rubs and secreted a little mucous
during the observation period (Fig. 3). In contrast, the NCS
and NSAR groups of rats presented significantly increased
numbers of sneezes (NCS 20.4 ± 5.3, NSAR 23.7 ± 9.2
vs. NS 5.6 ± 0.8, p \ 0.01) and rubs (NCS 65.3 ± 20.7,
NSAR 69.5 ± 17.9 vs. NS 32 ± 17.4, p \ 0.01), accom-
panied by increased amounts of nasal secretion (NCS
20.3 ± 5.7, NSAR 24.1 ± 4.4 vs. NS 5.9 ± 1.2, p \
0.001). However, the number of sneezes (NKR 7.2 ±
1.9 vs. NCS 20.4 ± 5.3, NSAR 23.7 ± 9.2, p \ 0.01) and
rubs (NKR 31.4 ± 8.9 vs. NCS 65.3 ± 20.7, NSAR
69.5 ± 17.9, p \ 0.01), and the amounts of secreted
mucous (NKR 7.1 ±2.3 vs. NCS 20.3 ± 5.7, NSAR
24.1 ± 4.4, p \ 0.001) in the NKR group of rats were
significantly less than those of the other AR rats. Therefore,
knockdown of NK-1R expression ameliorated AR-related
clinical symptoms in rats.
Knockdown of NK-1R expression inhibits eosinophil
infiltration and reduces serum IL-5 levels in rats
Next, we examined the impact of NK-1R silencing on
allergic inflammation in the nasal mucosa. We found that
the numbers of eosinophils in the NLF from the NSAR and
NCS groups of rats were significantly greater than
those from the NKR group (NCS 11.2 ± 2.7 9 106/L,
NSAR 10.4 ± 2.3 9 106/L vs. NKR 4.7 ± 1.2 9 106/L,
p \ 0.05), which was only slightly higher than, but not
Fig. 2 Immunohistochemistry analysis of NK-1R expression in the
nasal mucosa. The nasal mucosal tissue sections from different groups
of rats were stained with hematoxylin and eosin and imaged.
Representative images (magnification 9400) from individual groups
are shown.  Healthy control rats treated with saline, ` AR rats
treated with control siRNA, ´ AR rats treated with saline, ˆ AR rats
treated with NK-1R-specific siRNA
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significantly different from, those in the NS group (NKR
4.7 ± 1.2 9 106/L vs. NS 3.4 ± 1.1 9 106/L, p [ 0.05,
Fig. 4a). A similar pattern in the levels of serum IL-5 was
detected in the different groups of rats (NCS 199.3 ± 42.5,
NSAR 204.6 ±61.2 vs. NKR 111.2 ± 54.3, p \ 0.01;
NKR 111.2 ±54.3 vs. NS 106.7 ± 33.7, p [ 0.05,
Fig. 4b). These data indicated that induction of AR
recruited eosinophil infiltration and induced strong IL-5
responses in rats. Knockdown of NK-1R expression
reduced the levels of eosinophil infiltration and IL-5
responses in rats.
Discussion
In the present study, we found that induction of AR up-
regulated NK-1R expression in the nasal mucosa of rats,
which was associated with clinical symptoms and eosino-
phil-related nasal mucosal inflammation. Intranasal
treatment with NK-1R-specific siRNA effectively inhibited
NK-1R expression and mitigated AR-related clinical
symptoms and eosinophil inflammation in the nasal
mucosal tissues of rats. Our findings support the notion that
NK-1R is involved in nasal mucosal inflammation and
suggest that NK-1R may be a crucial mediator of the
development of AR. Indeed, the vascular permeability
induced by tachykinins in the nasal mucosa is primarily
mediated by NK-1R, and it can be controlled by local
application with a NK-1R antagonist [15]. NK-1/2 recep-
tors are both involved in the development of nasal
hyperresponsiveness in allergic rhinitis of guinea pigs [16].
Conceivably, modulation of NK-1R expression may be a
promising strategy for the intervention of AR.
SP acts as an important factor participating in the
pathogenesis of nasal mucosal inflammation, such as AR
[17–19]. SP can stimulate the release of inflammatory
mediators, including histamine and chemokines, which
recruit inflammatory infiltrates [20, 21]. Indeed, topical
administration of SP can induce AR symptoms and recruit
eosinophil infiltration in the nasal mucosal tissues of
healthy animals [6, 22].
Fig. 3 Knockdown of NK-1R expression mitigates AR-related
clinical symptoms in rats. After the last challenge, the numbers of
sneezes and nose rubs in individual rats were observed for 15 min,
and the amount of nasal secretions was collected for 5 min. Data are
expressed as the mean ± SD of individual groups (n = 8 per group)
of rats. NS Healthy control rats treated with saline, NCS AR rats
treated with control siRNA, NSAR AR rats treated with saline, NKR
AR rats treated with NK-1R-specific siRNA. *P\0.05 vs. NS group.
#P \0.05 vs. NCS or NSAR group
Fig. 4 Knockdown of NK-1R expression reduces the numbers of
eosinophil infiltrates in NLF and the levels of serum IL-5 in AR rats.
After the last challenge, the NLF was collected from individual rats
and the numbers of eosinophils in the NFL were measured (a). In
addition, the concentrations of serum IL-5 in individual rats were
determined by ELISA (b). Data are expressed as the mean ± SD of
individual groups (n = 8 per group) of rats from three separate
experiments. NS Healthy control rats treated with saline, NCS AR rats
treated with control siRNA, NSAR AR rats treated with saline, NKR
AR rats treated with NK-1R-specific siRNA. *P\0.05 vs. NS group.
#P \0.05 vs. NCS or NSAR group
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Capsaicin binds to the TRPV1 receptor to cause mem-
brane depolarization and massive SP depletion from the
presynaptic nerves [23]. Repeated treatment with capsaicin
can deplete SP in the nasal mucosa and relieve AR clinical
symptoms [24]. SP can bind to its NK-1R, which is
expressed by inflammatory cells and nasal mucosal epi-
thelial cells as well as vascular endothelial cells [9]. We
found that induction of AR significantly up-regulated NK-
1R expression in the nasal mucosal tissues, which was
associated with increased numbers of sneezes and nose
rubs and increased amounts of mucosal secretion in rats.
Our data were consistent with previous reports [9, 10].
Given that NK-1R is expressed by inflammatory cells and
nasal mucosal epithelial cells as well as vascular endo-
thelial cells [9], it is possible that the up-regulated NK-1R
expression in those cells increases their sensitivity to SP,
increasing nasal mucosal secretion, vasodilatation, plasma
extravasation, and inflammation. Therefore, our findings
and those of others strongly suggest that NK-1R is a
mediator of the pathogenesis of AR in rats.
Eosinophils and IL-5 are crucial for the development of
AR [25–27]. IL-5 is mainly produced from Th2 cells and/or
mast cells. IL-5 can recruit eosinophil infiltration in the
nasal mucosal tissue, where eosinophils can secrete cat-
ionic proteins, such as the major basic protein, peroxidase,
and neurotoxin, leading to tissue damage [28]. The
induction of AR increased the numbers of eosinophil
infiltrates in the nasal mucosal tissues, accompanied by
elevated levels of serum IL-5 in rats, further supporting the
importance of eosinophil infiltration and IL-5 responses in
the development of AR. SP can synergistically enhance
eosinophil infiltration mediated by IL-5 and stimulate
human eosinophil degranulation and the release of neuro-
toxin and peroxidase, which can be abolished by NK-1R
antagonists [29–31]. Indeed, administration of SP enhances
IL-5 mRNA transcription in nasal mucosal tissues of
patients with allergic rhinitis [32]. In addition, NK-1R can
regulate the activation of mast cells through FceRI sig-
naling [33]. Therefore, therapeutic targeting of SP or NK-
1R to inhibit IL-5 expression and eosinophil infiltration
may be valuable for the intervention of AR.
To further study the role of NK-1R in AR, we treated
AR rats intranasally with NK-1R-specific siRNA and found
that treatment with siRNA not only dramatically reduced
the levels of NK-1R expression, but also relieved AR-
related clinical symptoms in rats. In addition, knockdown
of NK-1R significantly reduced the numbers of eosinophil
infiltrates in the nasal mucosal tissues and the levels of
serum IL-5 in rats. Our data were consistent with previous
findings that treatment with a NK-1R antagonist inhibits
allergic nasal mucosal inflammation [34]. Treatment with
a dual antagonist for the NK1/2 receptors suppresses
the development of nasal hyperresponsiveness, and
intravenous administration of NK-1R receptor antagonist
before the intranasal application of SP inhibits SP-induced
nasal obstruction [16, 34]. Therefore, knockdown of NK-
1R in Th2 cells may directly attenuate their function and
reduce IL-5 production. Given that IL-5 is predominantly
secreted by Th2 cells and mast cells, it is possible that
knockdown of NK-1R may inhibit mast and other cell
activation, lower IL-5 expression and reduce eosinophil
infiltrates in the nasal mucosal tissue of rats. We are
interested in further investigating whether knockdown of
NK-1R expression can inhibit Th2 and mast cell infiltration
in the nasal mucosa in AR rats.
The siRNA approach is an effective and specific tech-
nology for reducing target gene expression. A large
research effort has been directed at developing potential
siRNA therapeutics for the treatment of viral infections,
cancer, and neurodegenerative diseases [35, 36]. Although
the effect of siRNA has been demonstrated in animal
models, the efficacy of siRNA-based therapeutic strategies
in humans has not been clarified and is currently being
tested in ongoing clinical trials [37]. In our study, we
designed a specific NK-1R-siRNA and demonstrated that
intranasal administration of NK-1R effectively inhibited
NK-1R expression in rats. Therefore, our findings suggest
that siRNA-based NK-1R-specific therapy may be feasible
for the intervention of AR.
In summary, our data indicated that intranasal treatment
with NK-1R-specific siRNA not only dramatically reduced
the levels of NK-1R expression, but also relieved AR-related
clinical symptoms and nasal mucosal inflammation in rats.
Hence, our findings support the notion that SP and NK-1R
are crucial for the development of AR. We recognize that our
study had limitations, such as not examining different types
of inflammatory cells, such as Th2, mast cells, neutrophils
and macrophages in the nasal mucosa, and the lack of
detailed studies of molecular mechanisms by which knock-
down of MK-1R affected Th2 cell function and IL-5
production and the signal pathways involved in nasal
mucosal epithelial cell function in rats. Therefore, further
studies to address these questions are warranted.
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